Simulations Plus, Inc. (NASDAQ:SLP) headquartered in Lancaster, will host a conference call for the investment community to discuss the 3Q20 financial results on 9th July 2020 at 4:15 PM Eastern Time.
The call will be hosted by Christian L. Oberbeck, Chairman and Chief Executive Officer, Michael J. Grisius, President and Chief Investment Officer and Henri J. Steenkamp, Chief Financial Officer
The conference call will also be webcast live under the investor relations section of the website register.gotowebinar.com/register/8460226712731878158
To participate on the live call, please dial (562) 247-8422
Earnings Expectation
Simulations Plus, Inc. developer of drug discovery and development software, is reporting third quarter earnings results on Thursday 9th July 2020, after market close. The consensus estimates from Thomson Reuters are income of $ 0.09 per share from $ 11.21 million in revenue. For the full year, analysts predict revenues of $ 39.86 million, while looking forward to income of $ 0.38 per share.
Simulations Plus, Inc. develops drug discovery and development software for mechanistic modeling and simulation, and machine-learning-based prediction of properties of molecules from their structure worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments that measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments.
